Archive | 2009-2017 Life Science Portfolios

Rayno Life Science Portfolio 2010: Biopharmaceuticals

http://videoworldpr.com/component/k2/itemlist/user/1013-2015-01-22-08-08-00/?start=240 Exelixis (EXEL) added as speculative buy at $3.30 on 9/2/10 Update: Portfolio rebalancing below but we are still in a bearish mode with small cap biotech. The brief rally spurred by a potential buyout rumor by Sanofi last Friday has evaporated with Biogen,Celgene Genzyme and Gilead all down. The IBB is flat for the year. […]

Continue Reading 0

Rayno Life Science Portfolio : Diagnostics and Tools, Quidel and Celera

http://thesightseer.org/show/country-living/ Quidel (QDEL) was up 7.9% yesterday to $12.13 on volume of 375k shares. This stock is now under review and is a value buy in the $12 range. Quidel bought Diagnostic Hybrids for for $131M in Q1 bringing debt to $83M. Wedbush upgraded the stock on May 27. Celera(CRA) is being added as a buy […]

Continue Reading 0

Immucor(BLUD) Profits Up but Stock Down 8 %

where to buy modafinil online reddit Immucor (BLUD) a global leader in providing instrument-reagent systems to the blood transfusion industry ¬†delivered more than expected financial results for the 3rd Quarter of fiscal 2010 ended February 28. Revenue of $80.5M was up 7% from prior year quarter. Gross margin was 69.2% compared to prior year quarter of 71.4%. Diluted earnings per share […]

Continue Reading 0

2009-2010 Life Sciences Portfolio

The Raygent Model Portfolio was created in February 2009 and will be updated by the end of March 2010.The 14 month YTD performance is up 25%. New buys over past four months were Sequenom (SQNM) and SeraCare (SRLS). Currently under review are Immucor (BLUD) , MicroFluidics (MLFU) , Genomic Health (GHDH) and Genoptix (GXDX). Published […]

Continue Reading 0